Rhabdomyosarcoma (RMS) is a paediatric soft-tissue sarcoma arising from skeletal muscle precursors coexpressing markers of proliferation and differentiation. Inducers of myogenic differentiation suppress RMS tumourigenic phenotype. The Notch target gene HES1 is upregulated in RMS and prevents tumour cell differentiation in a Notch-dependent manner. However, Notch receptors regulating this phenomenon are unknown. In agreement with data in RMS primary tumours, we show here that the Notch3 receptor is overexpressed in RMS cell lines versus normal myoblasts. Notch3-targeted downregulation in RMS cells induces hyper-phosphorylation of p38 and Akt essential for myogenesis, resulting in the differentiation of tumour cells into multinucleated myotubes expressing Myosin Heavy Chain. These phenomena are associated to a marked decrease in HES1 expression, an increase in p21
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Paediatric RMS includes two major histological subtypes, embryonal and alveolar. Approximately 70% of alveolar RMS harbour chromosomal translocations such as t(2;13) or t(1;13), resulting in PAX3-FKHR or PAX7-FKHR fusion products, and were considered the most aggressive forms. By contrast, recent studies demonstrated that fusionnegative alveolar tumours were molecularly and clinically indistinguishable from embryonal ones. 2 Despite aggressive treatment, the management of paediatric RMS, especially the fusion-positive alveolar form, often metastatic at diagnosis and resistant to conventional therapy, remains challenging.
Similar to myogenic progenitors, RMS cells express muscle-differentiating factors but have lost the ability to terminally differentiate thus proliferating indefinitely. 3 Promoting redifferentiation of RMS to its original skeletal muscle tissue type is a recognized strategy to suppress transformed phenotype. 4, 5 In this view, gaining of knowledge on pathways involved in physiological myogenesis and that are found deregulated in RMS is pivotal for the identification of selected factors sustaining the pro-tumoural phenotype.
Notch proteins have fundamental roles in balancing proliferation versus differentiation. 6 Mammals harbour four Notch genes, each encoding a type I transmembrane Notch receptor paralog (Notch1-4). Notch activation begins with the binding of the extracellular domain of transmembrane ligands of the Delta and Jagged family to Notch receptors on neighbouring cells. This interaction allows Notch to undergo sequential proteolytic cleavages, the last one being mediated by a g-secretase complex that releases an active Notch intracellular domain (Notch   IC   ) . Notch IC translocates into the nucleus, where it activates the expression of target genes together with the DNA-binding RBP-Jk protein (also known as CSL, for CBF1/Su(H)/Lag1). 7 Among Notch target genes are those encoding the enhancer of split group of transcriptional repressors, which are termed hairy and enhancer of split (HES) 1-7 and HES-related repressor (HEY) 1,2 and L in mammals. 8 Notch activation in muscle progenitors impairs the transcription of myogenic factors, preventing cell differentiation and promoting proliferation. 9 Consistently, inhibition of g-secretase activity leads to myoblasts differentiation. [10] [11] [12] Recently, Sang et al. 13 have shown that HES1 is upregulated in primary RMS and its inhibition, as well as the blockade of g-secretase activity, induces cell cycle arrest and differentiation of RMS cell lines. Combined with the fact that Notch signalling modulates critical aspects of cancer progression in many types of tumours, 14 these data suggested that aberrant Notch signalling could underlie the development of RMS. However, the mechanism responsible for the anti-differentiative function of HES1 in RMS remained to be clarified. Here we identify the Notch3 receptor as a major player in this process. We report that, in agreement with data on RMS primary tumours, 15 Notch3 is overexpressed and activated in RMS cell lines compared with their normal counterpart. Moreover, downregulation of Notch3 in RMS cells induces inhibition of G1-to-S cell cycle progression resulting in skeletal muscle-like differentiation and the expression of myogenic markers such as Myosin Heavy Chain (MHC) and troponin. These processes follow a marked increase of p38 MAPK (mitogenactivated protein kinase) phosphorylation and cyclin-dependent kinase (CDK) inhibitor p21 Cip1 expression. HES1 is an important downstream effector of these phenomena as (i) HES1 level is noticeably decreased after Notch3 silencing and (ii) HES1-forced overexpression partly overcomes Notch3 depletion-associated phenotype. Finally, Notch3 silencing in RMS cells compromises their tumourigenic ability in vitro and tumour growth in vivo. Taken together, these results provide evidence for a pro-tumourigenic role of Notch3 signalling pathway in RMS.
Results
Notch signalling components are transcriptionally deregulated in human RMS cell lines and primary tumours. Two PAX3-FKHR fusion-positive alveolar (RH30 and RH41) and three fusion-negative embryonal (RD, RH18 and A204) human RMS cell lines were characterized for the expression and activation of Notch components and compared with healthy primary human skeletal myoblasts (SkMC, control cells).
As reported in Figure 1a , all tumour cell lines had increased levels of both Notch1 and Notch3 activated forms , Notch1 IC and Notch2 IC bands as decreased in nuclear-enriched extracts from cell treated with an inhibitor of g-secretase (i.e., DAPT). In RD cells, both Notch3
IC and Notch2
IC
were detected in cytoplasmic fractions as well, suggesting cell type-specific regulation of Notch signalling/trafficking. 16 Consistently, Notch1 and Notch3 were transcriptionally upregulated in all tumour cell lines whereas Notch2 mRNA level was only modestly increased in three tumour cell lines, that is, embryonal RH18 and A204 and alveolar RH41 (Figure 1c ). In agreement with Sang et al., 13 the Notch target gene HES1 was significantly upregulated in all RMS cell lines. Notch ligand Jagged1 was overexpressed with different extents (Figures 1a and b) whereas Delta1 and Notch4 IC were under the threshold of detection in both control and RMS cells (data not shown). These findings suggest that Notch1 and Notch3 signalling could be deregulated in RMS cell lines, irrespective of their subtype.
Notch3 silencing induces myogenic differentiation of RMS cells. Murine and human myoblasts have been shown to lose the ability to undergo skeletal muscle differentiation when Notch3 is activated; conversely Notch3 downregulation preserves this differentiation potential. 17 Therefore, we focus on Notch3 to evaluate whether it could be involved in the inability of RMS cells to terminally differentiate. To this end, Notch3 was silenced and in vitro RMS cell differentiation was monitored. As shown in Figures 2a, b and c, numerous multinucleated fibres were detected in Notch3 siRNAtransfected RD and RH30 cell lines along with de novo expression of MHC and troponin, consistent with myotube fusion. This effect was associated with an increase of the muscle marker Myogenin in both cell lines (Figure 2d , right panel). Moreover, Notch3 silencing resulted in enhanced phosphorylation of p38 MAPK and serine-threonine kinase Akt, both essential for terminal muscle differentiation [18] [19] [20] ( Figure 2d , right panel). Consistently, also the Akt downstream target serine-threonine kinase mTOR (mammalian target of Rapamycin) was hyper-phosphorylated. 20 Notch3 siRNA efficiency was attested by drastic decrease of mRNA levels (data not shown) and the reduced Notch3 IC and HES1 protein levels in both cell lines (Figure 2d ). Silencing Jagged1 by siRNA lowered Notch3 IC and HES1 protein levels, especially in RD cells, suggesting that Notch3 activation is due, at least in part, to the binding with this ligand (Figure 2e ).
Despite the fact that Notch1 has not been reported significantly overexpressed in RMS primary tumours with respect to muscle tissue, 15 it appeared activated in RMS cell lines (Figures 1a and b) . To clarify its role in RMS cells differentiation, we knocked down Notch1 expression and monitored the induction of myogenesis in RD and RH30 cells. Figures 2b and c) . Differently, neither increase in Myogenin levels nor myotube-like formation Altogether, these results suggest that Notch3 expression/ activation is able to prevent the differentiation of both alveolar and embryonal RMS cells. Downregulation of Notch3 reduces RMS cell proliferation and soft-agar colony formation. To evaluate the impact of Notch3 siRNA-induced differentiation on cell growth rate, cell proliferation and cell cycle were analyzed. Notch3 knockdown Figure 3) . We also observed that the ability of Notch3 siRNA-treated cells to form colonies in soft-agar was significantly impaired (Figure 3b ). Interestingly, forcing Notch3 activation by ectopic expression of a Notch3 IC in both RD and RH30 cell lines led to opposite molecular and functional results (data not shown). These findings strongly indicate that Notch3 expression promotes proliferation and supports tumourigenic features of RMS cells in vitro.
Consistently, cell cycle analysis showed that after Notch3 knockdown, about 80% of RMS cells were in G1 phase compared with only about 45% of control siRNA cells (Figure 4a ). Also the percentage of cells in S phase was reduced from about 45% to about 10% in both cell lines. In line with this, Notch3 silencing triggered a marked increase of p21
Cip1 as early as 24 h after treatment ( Figure 4b ). p21
Cip1 mRNA level was not significantly changed within 2 days from Notch3 depletion, ruling out early transcriptional effects (data not shown). As shown in Figure 4c , Notch3 silencing also caused an increase of the under-phosphorylated (active) form of the retinoblastoma tumour suppressor protein (pRb) and of the phosphatase and tensin homolog deleted on chromosome ten (PTEN). Consistent with a slowing down of cell proliferation, Notch3 siRNA also decreased extracellular signallingregulated kinases ERK1/2 phosphorylation in both cell lines compared with control siRNA. Collectively, these results suggest that Notch3 stimulates cell cycle progression by promoting the G1-to-S phase transition, and that it regulates the ERK pathway in RMS cells. HES1 has a role in Notch3 signalling in RMS cells. In the attempt to evaluate whether the function of Notch3 in RMS is mediated, at least in part, by HES1, we performed loss-and gain-of-function experiments either silencing or forcing the expression of HES1 in RMS cells. HES1 downregulation by siRNAs in RD cells led to an enhancement of p21
Cip1 levels 48 h after siRNA transfection (Figure 5a ). This happened although HES1 protein levels were modestly decreased 48 h after siRNAs treatment when transcript reduction reached about 60 and 70% in RD and RH30 cells, respectively, compared with control siRNA cells (data not shown). HES1 downregulation did not induce any increase in p21
Cip1 and Myogenin transcript levels up to 48 h after knocking down. In RH30 cells, these molecular modulations were undetectable. However, after 6 days of HES1 knocking down, multinucleated fibres positive for MHC were seen in both cell lines compared with control siRNA cells (Figure 5b) . Interestingly, reduction of HES1 levels in Notch3-depleted cells reinforced all these Then, we infected RMS cells with an adenovirus expressing both human HES1 and the GFP protein (AdHES1) 24 h after Notch3 silencing (see Supplementary Figure 3 for infection efficiency detection). A vector expressing only GFP (AdGFP) was the control vector. As shown in Figure 6a , p21Cip1 and Myogenin levels were downregulated 48 h after overexpression of HES1 in both Notch3 and control siRNA-treated cell lines compared with their AdGFP-infected counterparts. However, in Notch3 knocked down cells levels of both proteins remained higher than in control siRNA cells suggesting that (i) the efficiency of HES1 overexpression is not sufficient to completely block these molecular modulations and/or (ii) additional Notch3-dependent pathways collaborate with HES1.
However, consistent with these results, after normalization for the percentage of GFP-positive RD and RH30 cell populations, cell cycle analysis showed an about 10 and 20% increase of the percentage of HES1-overexpressing cells (AdHES1) in S phase and 22 and 35% in G2 phase compared with AdGFP control cells, respectively (Figure 6b , both panels and Supplementary Figure 4) .
Notably, RD cells overexpressing HES1 did not differentiate 6 days after infection (i.e., 7 days after siRNA treatment), as testified by the mutual exclusion of GFP and MHC expression (Figure 6c ). Instead, a small number of Notch3 siRNA RH30 cells overexpressing HES1 are still able to differentiate even if they formed thinner myotubes compared with AdGFP control ones.
These data indicate that HES1 knockdown partially mimics Notch3 downregulation in RMS cell lines and, coherently, HES1 forced expression partially counteracts Notch3-depletion effects. Therefore, they are supportive for a role of HES1 in the maintenance of Notch3-dependent pro-tumour effects in RMS.
Short-hairpin (sh)RNA-mediated Notch3 reduction decreases RMS tumour growth rate in vivo. In the attempt to evaluate whether Notch3 downregulation affects tumour growth in vivo, RH30 cells were transfected with a GFPexpressing plasmid encoding an shRNA against Notch3. In vitro, a 3 weeks transfection with such Notch3 shRNA resulted in the formation of persistent RH30 multinucleated GFP-positive cells ( Figure 7A, left) , where Notch3 activation was strongly reduced, as assessed in lysates from cells sorted according to GFP expression ( Figure 7A, right) . In addition, a marked decrease in the proliferation rate of Notch3 shRNA cells compared with control shRNA ones was observed (data not shown). Then, nude mice were inoculated with suspensions of RH30 cells containing a sub-population (B40%) of cells transiently transfected with Notch3 shRNA (Supplementary Figure 5) . The reason for using a mixture of cells is that in preliminary experiments, when we inoculated mice with 100% Notch3 shRNA-expressing cells no xenograft growth was Figure 7E ). In summary, we have shown that Notch3 knockdown induces myogenic differentiation and decreases tumourigenicity of RMS cells in vitro and in vivo, and that Notch3 controls cell cycle progression and the ERK and Akt pathways in RMS cells. Moreover, we have provided evidence that Notch3 effects in RMS cells are mediated, at least in part, by HES1. Our data indicate that Notch3 is pivotal to the choice between proliferation and differentiation in RMS cells. 
Discussion
In this study, we investigated the involvement of Notch signalling in the inability of RMS cells to complete the myogenic program. Consistently with data on primary RMS tumours, 15 we showed that Notch3 is overexpressed in RMS cell lines and abnormally activated in a ligand-dependent manner. We also provided evidences that there is a causal relationship between Notch3 expression and the tumourigenic properties of RMS cells in vitro, as Notch3 silencing is sufficient in restoring myogenesis and inhibiting cell cycle progression and anchorage-independent growth. Moreover, All these observations are consistent with recent studies demonstrating that (i) Notch3 is highly expressed in the most immature subpopulation of satellite stem cells that gives rise to skeletal muscle-committed precursors, 21 (ii) the expression of Notch3 in satellite cells is mutually exclusive with that of early skeletal muscle markers such as MyoD and Myogenin, 21, 22 (iii) the expression of Notch3 in proliferating myoblasts is lost during the induction of differentiation 22 and, conversely, (iv) the induction of Notch3 expression in myoblasts correlates with the loss of skeletal muscle features blocking myogenesis. 17 In vitro Notch3 knockdown resulted in both alveolar and embryonal cells in an early significant overexpression of the p21 Cip1 protein, along with an increase of Myogenin and the hypo-phosphorylated form of pRb, as reported during physiological skeletal muscle differentiation. 23, 24 Interestingly, alveolar cells showed lower induction of p21
Cip1 and needed sustained levels of Notch3 silencing compared with embryonal ones. Consistent with the notorious context-dependence of Notch signalling, this finding is possibly related to high Notch1 and/or fusion proteins expression in alveolar RMS.
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Notch3 knockdown also increased phosphorylation of p38 MAPK, previously shown to be inhibited by Notch in myoblasts, 26 Akt and Akt-target mTOR, which all cooperate to myogenesis. [18] [19] [20] 23, 27 Although the difference between the molecular mechanisms underlying Akt/mTOR-dependent mitogenesis or myogenesis in RMS needs to be fully elucidated, these results provide insights on Notch-Akt/mTOR pathway cross-talk in this soft-tissue sarcoma suggesting potential therapeutic applications. 28 We also noticed an increase in PTEN, reported to be regulated by Notch pathway in several cancer types, 29, 30 and that might act as a negative feedback associated with prolonged Akt activation. 31 However, the concomitant increase in the less active Ser 380 -phosphorylated PTEN form could control the PTEN-PI3K-Akt axis to avoid suppression of the myogenic process. 32 Notably, Notch3 depletion was consistently associated with strong inhibition of HES1 expression, suggesting that Notch3 regulation of RMS cells differentiation and proliferation occurs, at least in part, through HES1. Indeed, (i) forcing the HES1 expression in Notch3 knocked down RMS cells partially overcame, whereas (ii) co-downregulation of Notch3 and HES1 facilitated Notch3-depletion effects. These observations demonstrate that HES1 lowering is necessary for the Notch3 silencing-dependent anti-proliferative and promyogenic effects, and support HES1 as a downstream effector of Notch3 signalling in RMS.
This feature is specific of the Notch3 paralog as neither the downregulation of Notch1, also overexpressed and activated in RMS cell lines compared with myoblasts, nor that of Notch2 resulted in HES1 protein level reduction.
Such differential effects of Notch receptors have been reported in several types of cancer and appear contextdependent. Among these, in breast cancer, medulloblastoma, multiple myeloma and mesothelioma, some Notch paralogs have an oncogenic role whereas others behave as tumour suppressors modulating differentially downstream targets. 33 The mechanism regulating these differential functions is under intense investigation and could be related to a diverse transcriptional activity but also to the ability to bind the RBP-jk/ CBF-1 complex and/or to displace corepressors from the transcriptional complex. 14 Increasing evidence suggests that oncogenesis in RMS involves multistage dysregulation of several signalling proteins. 34 It is likely that other pathways cross-talk with Notch3 during RMS development. The cross-talk of different Notch-receptors pathways in tumours has been previously reported. 35 In this regard, we cannot exclude that Notch1 cooperates with Notch3, at least in the embryonal cells. However, recent data showed no significant differences in the expression of Notch1 mRNA levels in primary RMS tumours compared with normal muscle tissues, 15 suggesting that this Notch paralog could have a minor role in RMS pathogenesis. In this regard, it is conceivable that Notch1 upregulation in RMS cell lines could be ascribed to the molecular features of tumour tissues from which these cells derive. On the basis of this possibility, in RMS tumours with high Notch1 expression/ activation, Notch1 and Notch3 signalling pathways could cooperate to sustain the tumourigenic phenotype.
Strikingly, Myogenin expression was severely impaired after Notch2 downregulation in RMS cell lines. This observation is consistent with findings showing similar Notch2 mRNA and activation levels in RMS cell lines as compared with normal myoblasts, and with the evidence that Notch receptors can have differential and even opposite roles in the same type of cancer. 30 Future studies could dissect the specific role of each Notch paralog in RMS and Notch3-dependent direct and indirect effects.
Accordingly to the in vitro results, after injection of tumour cells (i.e., 2 Â 10 6 cells per injection), we noticed that xenografts formed by the cell population including Notch3 shRNA cells grew more slowly compared with control ones. Moreover, the lower percentage of GFP-positive cells found in Notch3 shRNA/ wt xenografts suggests that they resulted mostly from wild-type untrasfected cells with respect to control shRNA/wt ones. The evidence that xenografts containing Notch3-depleted population showed GFP cells that remain viable could be explained by the polyclonal character of the injected cell population, in which the level of Notch3 knockdown was heterogeneous and, possibly, in certain cells could not be sufficient to block cell engraftment and proliferation. However, Notch3 downregulation even in a fraction of cells affects the in vivo growth of alveolar RMS cells that are highly resistant to treatments.
Altogether, these results offer new insights into the deregulation of the myogenic program in the pathological context of RMS. Our results appear also relevant under a clinical translational point of view, as increasing evidence point out on the identification of small molecules and inhibitors specific to each Notch receptor. 36 Notch3-selective inhibition, as reported for a preclinical model of lung cancer, 37 could be, therefore, evaluated as potential adjuvant strategy in the treatment of chemotherapy-resistant RMS. Notch3-targeted therapy could potentially reduce possible toxic effects of complete Notch signalling pathway blockade. 37 In conclusion, our data identify Notch3 as an inducer of the dysregulated differentiative program in RMS providing evidence that its blockade restores myogenesis and prevents tumourigenic potential of tumour cells, thus suggesting novel therapeutic approaches. Western blotting. Western blotting was performed on whole-cell lysates as previously described. 38 See Supplementary Methods for antibodies and additional details.
Nuclear fraction-enrichment. Cells were lysed in cytoplasm lysis buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.2 mM EDTA and 1 mM DTT), containing protease inhibitors, 0.5 mM phenylmethylsulfonylfluoride (PMSF) and 0.6% Nonidet P-40 (Sigma Chemical Co., St. Louis, MO, USA). Lysates were centrifuged at 10 000 r.p.m. for 10 min at 4 1C, and the supernatants (cytoplasmic fractions) were split into aliquots and rapidly frozen. The nuclear pellet was washed in buffer A without Nonidet P-40 and finally resuspended in nuclear lysis buffer B (20 mM HEPES pH 7.9, 0.4 M NaCl, 2 mM EDTA, 1 mM DTT), containing protease inhibitors and 1 mM PMSF (Sigma Chemical Co.). Samples were incubated on ice for 30 min and centrifuged at 13 000 r.p.m. for 10 min at 4 1C; the supernatants (nuclear fractions) were split into aliquots and rapidly frozen. The remaining pellets, containing DNA as well as proteins tightly associated with DNA, were washed in reticulocyte buffered buffer (RSB: 10 mM NaCl, 10 mM Tris-HCl pH 7.5 and 1.5 mM Real time RT-PCR. Total RNA was extracted using TRizol (Invitrogen, Carlsbad, CA, USA) and analyzed by real-time RT-PCR as described. 39 See Supplementary Methods for primer sequences and details.
Transient RNA interference. Cells were transfected with double-stranded synthetic 21-mer RNA oligonucleotides (siRNA) against Notch3 (Hs01_00101285; Sigma Chemical Co.) or fluorescein-labeled non-targeting siRNA control (100 nM final concentration) using Oligofectamine (Invitrogen) according to manufacturer's recommendations. The efficacy of siRNA transfection was assessed by visualization of fluorescent cells under an Eclipse TE200 microscope (Nikon, Sesto Fiorentino, Firenze, Italia) and images were acquired through Metamorph software version 7.1 (Crisel, Roma, Italia). JAG1 silencing was performed at 100 nM (final concentration) using Silencer Select siRNA reagents (Applied biosystems, CA, USA/Ambion, TX, USA).
ON-TARGETplus SMART pool siRNA (Thermo Fisher Scientific, Lafayette, CO, USA), were used for downregulating HES1.
Immunofluorescence. Immunofluorescence for visualizing MHC was performed as previously described 38 using the MF-20 antibody (Developmental Studies Hybridoma Bank at the University of Iowa, Iowa City, IA, USA). Briefly, cells were washed three times in PBS, fixed for 10 min in 4% PFA and permealized for 5 min with 0.2% Triton X-100 in PBS. After 30 min in PBS containing 3% bovine serum albumin, slides were incubated for 1 h at room temperature with the MF-20 antibody against myosin heavy chain (MHC; DSHB, USA). After two washing in PBS, cells were treated with a fluorescein-linked secondary antibody. After being stained for 2 min with 200 ng/ml DAPI in PBS, chamber slides were mounted in GelMount (Biomeda, Foster City, CA, USA). Images were acquired with an Eclipse E600 fluorescence microscope, through LUCIA software version 4.81 (Nikon, Sesto Fiorentino, Firenze, Italy).
Cell proliferation and cell cycle assay. Cells were transfected at 24 h after seeding (Day 0) with siRNAs, harvested and counted at the reported time points. For cell cycle assay, the 5-ethynyl-2 0 -deoxyuridine (EdU) incorporation was performed using Click-iT EdU Flow Cytometry assay Kit (Invitrogen), and cells were analyzed with flow cytometry using a FACSCantoII and a FACSDiva 6.1 software (BD Biosciences, San Josè, CA, USA). For adenoviruses infections, GFP-positive cells' cell cycle was evaluated using propidium iodide staining and flow cytometry (FCM) analysis. Cells were harvested by trypsinization, washed in cold phosphate buffered saline (PBS) 1 Â , fixed in 50% PBS and 50% acetone/methanol (1 : 4 v/v) for at least 1 h, and, after removing alcoholic fixative, stained with a solution containing 50 mg/ml PI and 100 mg/ml RNase (Sigma Chemical Co.) for 30 min at room temperature, in dark. Samples were then measured by using a FACScan cytofluorimeter. Twenty thousand events per sample were acquired.
Soft-agar colony formation assay. After 48 h of transfection with Notch3 siRNA or control siRNA, RMS cells were assayed for their capacity to form colonies in soft-agar as previously described. 38 Briefly, a total of 2 Â 10 4 or 3 Â 10 4 cells were suspended in DMEM (10% FCS) containing 0.35% Noble agar (Sigma Chemical Co.). Cells were plated on a layer of 0.7% Noble agar in DMEM (10% FCS) onto a 35-mm petri dish. Medium was refreshed every 5 days. On week 4, the number of colonies per field was counted under the contrast-phase Eclipse E600 microscope (Nikon). Two independent experiments were carried out in triplicate.
Adenovirus infection. A recombinant, replication-deficient adenoviral CMV bicistronic vector expressing both human HES1 (AdHES1) and the green fluorescent protein (GFP) (a gift of GP Dotto) was used to infect RD and RH30 cells (100 plaque-form units per cell) as described. 40 A vector expressing only the reporter gene GFP (AdGFP) (a gift of G Toietta) was used as control. The efficiency of infection was determined analysing the percentage of GFP-positive cells with flow cytometry using a FACSCantoII and a FACSDiva 6.1 software (BD Biosciences). Xenograft experiments. Athymic 6-week-old female BALB/c nude mice (nu þ \nu þ ) were purchased from Charles River (23885 Calco (Lecco), Italy). Procedures involving animals and their care were conformed to institutional guidelines that comply with national and international laws and policies (EEC Council Directive 86\609, OJ L 358, 12 December 1987). RH30 cells transfected with Notch3 or CTR shRNA plasmids were transfected again 24 h later and allowed to grow for additional 24 h. The efficiency of transfection was determined by flow cytometry at this time. Cells (2 Â 10 6 ) were injected subcutaneously into the posterior flanks of nude mice in a cold mixture of PBS\Matrigel (ratio 1 : 1). At 2 weeks after the tumours became palpable, mice were sacrificed, xenografts were removed and tumour volume was measured as described. 35 Western blotting on total lysates from RMS xenografts were performed by pulling three Notch3 or CTR shRNA-derived specimens from snap frozen tissues.
Immunohistochemistry of xenograft samples. Serial 5 mm sections from paraffin-embedded tumours and control tissues were deparaffinized and antigen retrieval was performed for 25 min at 98 1C with citrate pH6. After endogenous peroxidase blocking at room temperature (RT), 3-5% BSA or 5% goat serum in Tris-buffered saline was applied for non-specific site blocking. Additional blocking was performed using Biotin Blocking System (DAKO Carpintera, CA, USA). Sections were incubated with anti-GFP (Clontech, Mountain View, CA, USA), anti-Ki67 (Novocastra Laboratories Ltd, Newcastle upon Tyne, UK) antibodies and the appropriate secondary antibodies. Positive reactions were visualized by incubation with diaminobenzidine (DAB chromogen kit, DAKO Carpinteria, CA, USA). Negative controls were done by treating serial cross-sections simultaneously with isotype non-specific IgG or omitting the primary antibody. Section were then dehydrated and mounted in non-aqueous mounting medium. Levels of GFP expression were semi-quantitatively quantified at 400 Â magnification by scoring Notch3 inhibits rhabdomyosarcoma differentiation L Raimondi et al
